News & Media 4th Jun 2024

GST probe wing set to widen scrutiny of pharma companies

Authors

Darshan Bora Partner | Bengaluru

Latest Thought Leadership

News & Media 25th Jun 2024

Misleading Ads: Ambiguous Self-Declaration Rules Leave Advertisers in Compliance Limbo

Read More
News & Media 25th Jun 2024

Budget 2024 expectations: Will the government increase Section 80C limit

Read More
News & Media 25th Jun 2024

MC Exclusive: FSSAI calls for strict compliance of food safety protocols after alarming contamination reports

Read More
News & Media 25th Jun 2024

Budget 2024: AIFs seek tax parity with FPIs

Read More

The Directorate General of GST Intelligence (DGGI) is set to intensify the scrutiny of suspected tax evasion by pharmaceutical companies, over non-payment of dues. In addition to the notices sent , the DGGI is likely to ask many more companies to explain what it perceives as under-payment of tax by them in the current year. The notices could pertain to non-payment of GST on brand transfer sales, claiming fake input tax credit (ITC) on expired drugs and for business support services, and non-payment under the reverse charge mechanism.

Financial Express’s Priyansh Verma writes on “GST probe wing set to widen scrutiny of pharma companies” with insights from our Partner Jignesh Ghelani.

Read the article here